Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 1, 2010, Pages 28-33

  Rimon, Gilad ^a,b   Sidhu, Ranjinder S ^a   Lauver, D Adam ^a   Lee, Jullia Y ^a   Sharma, Narayan P ^a   Yuan, Chong ^a   Frieler, Ryan A ^a   Trievel, Raymond C ^a   Lucchesi, Benedict R ^a   Smith, William L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Adrenic acid; Arachidonic acid; Nonsteroidal antiinflammatory drugs; Platelet; Prostaglandin

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; DIMER; IBUPROFEN; INDOMETACIN; MONOMER; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE;

ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; CATALYSIS; CONTROLLED STUDY; DOG; DRUG WITHDRAWAL; ENZYME BINDING; EX VIVO STUDY; HEART PROTECTION; HUMAN; IN VITRO STUDY; LOW DRUG DOSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROCESSING; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT WITHDRAWAL; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOGS; HUMANS; ISOENZYMES; MODELS, MOLECULAR; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN SUBUNITS;

CANIS FAMILIARIS;

EID: 76249130338     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0909765106     Document Type: Article

References (48)

1. van der Donk W, Tsai A, Kulmacz R (2002) The cyclooxygenase reaction mechanism. Biochemistry, 41(52):15451-15458.
2. Rouzer C, Marnett L (2003) Mechanism of free radical oxygenation of polyunsaturated fatty acids by cyclooxygenases. Chem Rev, 103(6):2239-2304.
3. Smith WL (2008) Nutritionally essential fatty acids and biologically indispensable cyclooxygenases. Trends Biochem Sci, 33(1):27-37.
4. Schneider C, Pratt DA, Porter NA, Brash AR (2007) Control of oxygenation in lipoxygenase and cyclooxygenase catalysis. Chem Biol, 14(5):473-488.
5. Rouzer CA, Marnett LJ (2008) Non-redundant Functions of Cyclooxygenases: Oxygenation of Endocannabinoids. J Biol Chem, 283(13):8065-8069.
6. Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest, 116(1):4-15.
7. Yuan C, Rieke CJ, Rimon G, Wingerd BA, Smith WL (2006) Partnering between monomers of cyclooxygenase-2 homodimers. Proc Natl Acad Sci USA, 103(16):6142-6147.
8. Yuan C, et al. (2009) Cyclooxygenase allosterism, fatty acid-mediated cross-talk between monomers of cyclooxygenase homodimers. J Biol Chem, 284(15):10046-10055.
9. Kulmacz RJ, Lands WEM (1985) Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J Biol Chem, 260(23):12572-12578.
10. Prusakiewicz J, Duggan K, Rouzer C, Marnett L (2009) Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid. Biochemistry, 49:7353-7355.
11. Rosenstock M, Danon A, Rimon G (1999) PGHS-2 inhibitors, NS-398 and DuP-697, attenuate the inhibition of PGHS-1 by aspirin and indomethacin without altering its activity. Biochim Biophys Acta, 1440(1):127-137.
12. Rosenstock M, Danon A, Rubin M, Rimon G (2001) Prostaglandin H synthase-2 inhibitors interfere with prostaglandin H synthase-1 inhibition by nonsteroidal antiinflammatory drugs. Eur J Pharmacol, 412(1):101-108.
13. Burde T, Rimon G (2002) On the interaction of specific prostaglandin H synthase-2 inhibitors with prostaglandin H synthase-1. Eur J Pharmacol, 453:167-173.
14. Ouellet M, Riendeau D, Percival MD (2001) A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci USA, 98(25):14583-14588.
15. K Wilner, et al. (2002) Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol, 42(9):1027-1030.
16. Gladding P, et al. (2008) The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol, 101(7):1060-1063.
17. Greenberg HE, et al. (2000) A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol, 40(12):1509-1515.
18. Catella-Lawson F, et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med, 345(25):1809-1817.
19. Solomon SD, et al. (2008) Cardiovascular risk of celecoxib in 6 randomized placebocontrolled trials: The cross trial safety analysis. Circulation, 117(16):2104-2113.
20. Hennan JK, et al. (2001) Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation, 104(7):820-825.
21. Copeland RA, et al. (1994) Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA, 91(23):11202-11206.
22. Laneuville O, et al. (1994) Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther, 271(2):927-934.
23. Rieke CJ, Mulichak AM, Garavito RM, Smith WL (1999) The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors. J Biol Chem, 274(24):17109-17114.
24. Walker M, et al. (2001) A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem J, 357(Pt 3):709-718.
25. LiuW, Cao D, Oh SF, Serhan CN, Kulmacz RJ (2006) Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J, 20(8):1097-1108.
26. Skarke C, et al. (2006) The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clin Pharmacol Ther, 80 (6):621-632.
27. Bae SK, et al. (2008) Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic study of Astrix in Korean healthy volunteers. Biomed Chromatogr, 22(6):590-595.
28. Gengo FM, et al. (2008) Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. J Clin Pharmacol, 48(3):335-343.
29. DeWitt DL (1999) Cox-2-selective inhibitors: The new super aspirins. Mol Pharmacol, 55 (4):625-631.
30. Suleyman H, Cadirci E (2008) Nimesulide is a selective COX-2 inhibitory, atypical nonsteroidal anti-inflammatory drug. Curr Med Chem, 15:278-283.
31. Luong C, et al. (1996) Flexibility of the NSAID binding site in the structure of human cylcooxygenase-2. Nat Struct Biol, 3:927-933.
32. Kurumbail RG, et al. (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature, 384(6610):644-648.
33. Malkowski MG, Ginell S, Smith WL, Garavito RM (2000) The x-ray crystal structure of prostaglandin endoperoxide H synthase-1 complexed with arachidonic acid. Science, 289:1933-1937.
34. Liu J, et al. (2007) Prostaglandin endoperoxide H synthases: Peroxidase hydroperoxide specificity and cyclooxygenase activation. J Biol Chem, 282:18233-18244.
35. Wada M, et al. (2007) Specificities of enzymes and receptors of prostaglandin pathways with arachidonic acid and eicosapentaenoic acid derived substrates and products. J Biol Chem, 282:22254-22266.
36. Bala M, et al. (2008) Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase. Biochem Pharmacol, 75(7):1472-1481.
37. Harman CA, Rieke CJ, Garavito RM, Smith WL (2004) Crystal structure of arachidonic acid bound to a mutant of prostaglandin endoperoxide H synthase-1 that forms predominantly 11-hydroperoxyeicosatetraenoic acid. J Biol Chem, 279(41):42929-42935.
38. Harman CA, et al. (2007) Structural basis of enantioselective inhibition of cyclooxygenase-1 by S-{alpha}-substituted indomethacin ethanolamides. J Biol Chem, 282(38): 28096-28105.
39. Otwinowski Z, Minor W (1997) Processing of x-ray diffraction data collected in oscillation mode. Method Enzymol, 276:307-326.
40. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr D, 61(Pt 4):458-464.
41. Adams PD, et al. (2002) PHENIX: Building new software for automated crystallographic structure determination. Acta Crystallogr D, 58(Pt 11):1948-1954.
42. Schuttelkopf AW, van Aalten DM (2004) PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D, 60(Pt 8):1355-1363.
43. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr, 60(Pt 12, Pt 1):2126-2132.
44. Laskowski RA, MacArthurMW, Moss DS, Thornton JM (1993) PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Cryst, 26:283-291.
45. Davis IW, et al. (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res, 35(Suppl 2):W375-383.
46. Sobolev V, Sorokine A, Prilusky J, Abola E, Edelman M (1999) Automated analysis of interatomic contacts in proteins. Bioinformatics, 15(4):327-332.
47. Laskowski R, et al. (1997) PDBsum: A web-based database of summaries and analyses of all PDB structures. Trends Biochem Sci, 22(12):488-490.
48. DeLano WL (2008) The PyMOL Molecular Graphics System (DeLano Scientific, Palo Alto, CA).